Clinical Trials on Multiple Chemical Sensitivity in Belgium

Total 460 results

Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, United Kingdom, Brazil, Spain, Sweden
Intergroupe Francophone du Myelome
Janssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology Association

Active, not recruiting

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)

Multiple Myeloma

Netherlands, France, Belgium
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Millennium Pharmaceuticals, Inc.

Completed

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Multiple Myeloma

United States, United Kingdom, Canada, Israel, France, Austria, Belgium, Germany, Ireland, Italy, Netherlands, Spain, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Millennium Pharmaceuticals, Inc.

Completed

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, France, Korea, Republic of, Canada, Belgium, New Zealand, Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (EXIST-1)

Tuberous Sclerosis | Subependymal Giant Cell Astrocytoma

United States, Belgium, Canada, Germany, Italy, Russian Federation, Netherlands, Poland, Australia, United Kingdom
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Denmark, Germany, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Multiple Myeloma

United States, Australia, Austria, Belgium, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland, Turkey, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States, France, United Kingdom, Belgium, Germany, Israel, Australia, Sweden, Canada, Netherlands, Austria, Ireland, Denmark
Amgen

Completed

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Multiple Myeloma

Korea, Republic of, China, Spain, Taiwan, United States, Netherlands, Australia, Singapore, New Zealand, United Kingdom, Israel, France, Japan, Italy, Czechia, Belgium, Argentina, Austria, Bulgaria, Canada, Germany, Greece, Hungary, M... and more
Sanofi

Completed

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)

Plasma Cell Myeloma

France, Spain, Greece, Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Japan, New Zealand, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden, Taiwan, Turkey, United...
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, Italy, China, Australia, Spain, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finland and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Celgene

Withdrawn

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Takeda

Completed

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Multiple Myeloma

France, Spain, United States, Taiwan, Korea, Republic of, Israel, Australia, Czechia, Hungary, Canada, Japan, Portugal, Singapore, United Kingdom, Italy, Sweden, Poland, Germany, China, Denmark, Greece, Thailand, Serbia, Turkey, Colombia, Russian Federation and more
Amgen

Completed

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)

Multiple Myeloma

Korea, Republic of, Spain, Taiwan, Canada, Australia, Israel, Italy, United States, Singapore, New Zealand, Japan, Thailand, Brazil, United Kingdom, Hungary, Czechia, Romania, Slovakia, France, Germany, Russian Federation, Bulgaria, Belgiu... and more
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Lymphoma | Multiple Myeloma

United States, Belgium, France, Germany, Italy, Japan, United Kingdom, Australia, Poland, Puerto Rico, Canada, Denmark, Hungary, Israel, Spain, Czechia, Ireland, Austria, Switzerland, Greece, Turkey, Romania, United Arab Emirates
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Israel, Germany, Italy, Czechia, Korea, Republic of, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Novartis Pharmaceuticals

Completed

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (PANORAMA-1)

Multiple Myeloma

China, United States, Italy, Taiwan, Egypt, Japan, Turkey, Germany, Netherlands, Canada, Australia, Austria, Israel, Sweden, United Kingdom, Korea, Republic of, Spain, Hong Kong, Thailand, France, Belgium, Norway, South Africa, Brazil, ... and more
Sol-Gel Technologies, Ltd.

Terminated

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Basal Cell Nevus Syndrome

United States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
Pfizer

Recruiting

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

Multiple Myeloma

China, Korea, Republic of, Taiwan, United States, France, Sweden, Australia, Japan, Spain, Czechia, United Kingdom, Canada, Germany, New Zealand, Italy, Poland, Netherlands, Austria, Mexico, Finland, Argentina, Belgium, Brazil, Greece, ... and more
Gilead Sciences

Completed

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

Alcoholic Hepatitis (AH)

Austria, United Kingdom, France, United States, Canada, Belgium, Switzerland
Celgene

Completed

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST)

Multiple Myeloma

Korea, Republic of, United States, France, Belgium, Canada, Spain, United Kingdom, Australia, Italy, New Zealand, China, Portugal, Switzerland, Taiwan, Austria, Greece, Germany, Ireland, Sweden
Celgene

Completed

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Multiple Myeloma

Belgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
Takeda

Active, not recruiting

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Multiple Myeloma | Autologous Stem Cell Transplant

United States, Spain, Australia, Czechia, Hungary, Taiwan, Italy, Denmark, Portugal, Singapore, Israel, Canada, France, Belgium, United Kingdom, Germany, Japan, Austria, Netherlands, Korea, Republic of, Poland, Greece, Colombia, Sweden, South Africa and more
Celgene

Completed

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Lymphoma | Lymphoma, Large B-Cell, Diffuse | Glioblastoma | Multiple Myeloma | Primary Central Nervous System Lymphoma | Pleiotropic Pathway Modifier

United States, Spain, Belgium, France, Italy
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
PellePharm, Inc.

Completed

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Basal Cell Nevus Syndrome

United States, Spain, Germany, United Kingdom, Italy, France, Belgium, Canada, Denmark, Netherlands
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
AstraZeneca

Completed

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

Croatia, Sweden, United States, Czech Republic, Spain, Hungary, United Kingdom, Belgium
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Durect
CTI Clinical Trial and Consulting Services

Completed

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM)

Alcoholic Hepatitis

United States, Australia, United Kingdom, France, Belgium, Austria
ImmunoGen, Inc.

Not yet recruiting

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian Cancer | Folate Receptor-Alpha Positive

United States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom

Clinical Trials on Multiple Chemical Sensitivity in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations